Choose Broker

Step 1
Choose a broker


Please enter your User ID and Password to place trade

Share or CFD

Step 2
Select the investment product you wish to purchase

OR

Share

Purchasing shares in a company buys you part ownership of that company. You're given the right to vote on who manages the company and receive a portion of company profits through the distribution of dividends.

Example: If a share price quote is $25, then that means one share is valued at $25.

Note: Shares are also referred to as stocks, equities and securities.

CFD

Is an abbreviation for "Contract for Difference". A CFD is a 'derivative' that is derived from the underlying value of the share price. A CFD’s allow you to go long (buy the CFD) or go short (sell the CFD).

CFD's give you leverage.

Example: Buying a CFD in XYZ provides you with an opportunity to purchase the shares at a variable rates such as 10 to 1 ratio instead of the full upfront share value cost i.e. paying $1,000 instead of $10,000.

Because CFDs are traded on margin, you must maintain the minimum margin level at all times.

Note: CFD’s are not recommended for novice traders.

Order Type

Step 3
Select your type of market order


Market Order

This is a type of order that instructs to buy or sell immediately at the best price available.

Limit Order

An order placed to buy or sell a set number of shares at a specified price or better.

Stop Order

This is an order that is executable once a set price has been reached. Once the order surpasses a particular point the order becomes a market order.

Stop Limit Order

An order placed that will be executed at a specific price or better after a given stop price has been reached. Therefore it combines the feature of a stop order with those of a limit order.

Order Period

Step 4
Select the time period that you want your trade to be live/active for.


G.T.C

Stands for good till cancelled. This means once the order is placed, the order will remain in place until someone cancels the order.

Day order

An order that if not executed, will stand until the end of the trading day.

One week

An order that will stand for a full week from the time it is placed, and then be automatically cancelled at the end of this period if it has not been executed.

One month

An order that if not executed, will stand for a full month.

End of week

An order that if not executed, will stand to the end of the trading week.

End of month

An order that if not executed, will stand to the end of the trading month.

End of year

An order that if not executed, will stand to the end of the year.

Quantity

Step 5
Select the value or quantity of how many shares you want to buy

Shares
@
$

Brokerage Fee: Please select broker first to calculate brokerage*.

Nominal Value:
$71.50 AUD

Risk Management

Step 6
Select what alarms (automatic exits) you want to protect both your investments and your profits.

Take Profit
$
OR
%
Stop Loss
$
OR
%
Trailing Stop Loss
%

Take Profit

Take-profit orders are used to lock in profits in the event the rate moves in a favorable direction. For example....

Stop Loss

Take-profit orders are used to lock in profits in the event the rate moves in a favorable direction. For example....

Trailing Stop Loss

Take-profit orders are used to lock in profits in the event the rate moves in a favorable direction. For example....

Confirm

Confirm
Please confirm your order

Buy -
Order Type -
Price -
Order Period -
Brokerage 8.00 AUD
Nominal Value -
Take Profit -
Stop Loss -
Trailing Stop Loss -
Trade Date -
There was a problem with your trade ticket. Please try again.
There was a problem submitting your trade ticket. Please try again in a minute.

Order Placed Successfully


Exit Orderpad        Place another trade
Current Price{{movement}} {{quote.Last.toFixed(3) == 0.000 ? quote['CF CLOSE'].toFixed(3) : quote.Last.toFixed(3)}} (20 minute delay)
Today's Change ${{quote['Net Change'].toFixed(3)}} ({{quote['% Change']}}%) Market is currently: {{quote['Price Qualifier Code'] == "OPN" ? "OPEN" : "CLOSED"}}
Open {{quote['Opening Price'].toFixed(3)}} Prev Close {{quote['Historic Close'].toFixed(3)}}
Today's High {{quote["Today's High"].toFixed(3)}} Today's Low {{quote["Today's Low"].toFixed(3)}}
Broker Consensus

No Data Available

  • Sell
  • Reduce
  • Hold
  • Buy
  • Strong Buy

BIODIEM LTD (BDM)
is a publicly listed company on the Australian Securities Exchange (ASX).


{{businessSummary}}

1 Day
Chart Type
Themes
Select Tool
Fill:
Line:
Axis Label:
  • Open:
  • High:
  • Close:
  • Low:
  • Volume:
  • Date:

News

No News Available

{{item.Body}}



General Overview

Company Overview

BioDiem is an Australian biopharmaceutical company that is focussed on developing and commercialising vaccines and infectious disease therapies.

Business Model: Our business model is to generate income from partnerships including with other vaccine and infectious disease treatment companies through existing and new licences to its LAIV vaccine and other technologies. We have an established influenza vaccine licensing business. Our revenue comes from licence fees and royalties on sales.

Our lead asset, the LAIV (Live Attenuated Influenza Virus) vaccine technology, is used for production of seasonal and pandemic influenza vaccines and is given intranasally. This technology is licensed currently to two commercial partners, in India and China, and is licenced to the World Health Organisation as part of the Global Pandemic Influenza Action Plan to Increase Vaccine Supply. Serum Institute of India's Nasovac-S™ is based on BioDiem's technology and is already marketed in India.

Our antimicrobial in development, BDM-I, is a synthetic compound targeting the treatment of serious human infections. BDM-I is active against a range of disease-causing micro-organisms. Key patents have been granted worldwide. BioDiem has benefited from work conducted by major research institutions in the United States that have undertaken studies of BDM-I. BDM-I is in the preclinical stage of development and BioDiem seeks co-development and co-investment partners for this technology.

Vaccine Licensing

Our lead product is the Live Attenuated Influenza Virus (LAIV) technology, which has been used to develop a novel intranasal vaccine for the prevention of seasonal and pandemic influenza. The technology is licensed to BioDiem by the Institute of Experimental Medicine (IEM) in St Petersburg, Russia.

Egg-based production: The version of the LAIV vaccine that uses chicken eggs for production is licensed to the World Health Organization for use in developing countries as part of the Global Pandemic Influenza Action Plan to Increase Vaccine Supply. This allows governmental and non-governmental organisations or private companies in those territories to produce seasonal and pandemic vaccines using eggs. In 2014 the egg-based LAIV vaccine was launched in India as Nasovac-S™ for protection against seasonal influenza. The LAIV technology is currently available for licence from BioDiem for developed world markets.

Cell-based production: A version of the vaccine which can be grown in tissue culture has completed first-in-human and proof-of-concept clinical trials in Europe as part of development for European registration. This technology is currently available for licence from BioDiem.

Development of the antimicrobial BDM-I

BDM-I is a novel compound which has shown impressive and broad activity in screening studies against a range of pathogenic micro-organisms including bacteria, fungi and protozoa. This data has come from research work conducted both in Australia and at leading US Government-backed research institutions.

The continued rise in antibiotic-resistant strains of bacteria such as MRSA, tuberculosis and gonorrhoea, and the increasing problem of clinical fungal infections, has led to significant interest in compounds which may address the lack of treatment options. Patents for BDM-I have been granted in the world's three largest patent jurisdictions, the US, Europe and Japan.

BioDiem is currently advancing BDM-I testing towards pre-clinical models of infectious diseases to demonstrate proof-of-concept and is seeking investment interest.

BioDiem's Other Programs

LAIV Viral Vector: a research stage program to investigate the potential for use of the LAIV as a viral vector to leverage its safety record. To request further information on the LAIV vector technology, please contact us.

SAVINE (scrambled antigen vaccine) technology: a technology to design and customise immune-stimulation proteins (antigens) for use in new vaccine design. To request further information on the SAVINE technology, please contact us.

BDM-E (epitalon): a tetrapeptide in development for back-of-eye (retinal) disease.

Business Developement

Partner Network
  • BioDiem's Global Partnering Network
  • Institute of Experimental Medicine (IEM), St. Petersburg, Russia
  • World Health Organization
  • Program for Appropriate Technology in Health (PATH) Program
  • Centers for Disease Control and Prevention (CDC)
  • Commercial partners
  • Australian research institutions
Institute of Experimental Medicine (IEM), St. Petersburg, Russia

The Institute of Experimental Medicine achieved international prominence early in the 20th century, when Nobel Prize winner Pavlov worked with dogs to establish the central nervous system basis of conditioned reflexes. The IEM has developed a broad-based research capacity in many areas of biology and medicine.

In 1956 the IEM's Department of Virology, under Academician Anatoly Smorodintsev, developed live vaccines against polio and in 1959 against measles. These vaccines and derivatives of them were used throughout Russia. After years of research in these and other areas of viral infection the Department turned its attention to influenza. They were able to develop an attenuated i.e. weakened form of the influenza virus which would serve as the basis for a safe, live influenza vaccine.

In 2001 the IEM entered into a Commercialisation Agreement with BioDiem Ltd, whereby worldwide rights (outside of Russia and the CIS) to the proprietary LAIV technology were granted to BioDiem in exchange for a royalty payment.

Prof Larisa Rudenko, the Head of the Dept of Virology at the IEM is a director of BioDiem. Prof Rudenko is a world expert in live attenuated influenza vaccine technology working closely with the CDC and WHO and other world-recognised influenza groups.

World Health Organization

BioDiem contributes to the WHO's Global Pandemic Influenza Action Plan by licensing the WHO to transfer an egg-based live attenuated influenza virus (LAIV) vaccine production technology to developing country manufacturers.

The agreement is a non-exclusive licence designed to support wider distribution of the LAIV influenza vaccine in developing countries. Whereas public sector usage is royalty-free, royalties flow to BioDiem from private sector sales. BioDiem has authorised the Institute of Experimental Medicine (IEM) and the Centers for Disease Control and prevention (CDC) to supply LAIV reassortants to the WHO for use by its sublicencees. The vaccines developed through the WHO program are manufactured using eggs. WHO has issued sublicences to the LAIV technology to three entities: the Serum Institute of India (SII), the Government Pharmaceutical Organization in Thailand (GPO), and Changchun BCHT Biotechnology Co. in China (BCHT).

In 2014 the Serum Institute of India launched its seasonal influenza vaccine, called Nasovac-S™, in India. This vaccine is a result of the WHO collaboration using BioDiem's technology and follows on from the SII launch of Nasovac for swine flu prevention in 2010. BioDiem receives royalty payments on sales of vaccines in the private market.

Facilitated by a grant from the WHO, work has been completed on a new laboratory fit-out at the Institute of Experimental Medicine to allow the Institute to handle highly pathogenic influenza (HPAI) strains e.g. H5N1 (avian or bird flu). Any material generated will be made available for use in developing countries under the World Health Organization's Global Pandemic Influenza Action Plan to Increase Vaccine Supply.

Program for Appropriate Technology in Health (PATH) Program

In August 2009 the Institute of Experimental Medicine (IEM), the originator of BioDiem's Live Attenuated Influenza Virus (LAIV) technology, entered into a development and collaboration agreement with the PATH, an international non-profit organization to develop prototype pandemic LAIVs for use in developing countries. The aim of this collaboration is to speed the development of live attenuated influenza vaccines that can be a safe, low-cost, and highly effective method for enabling real-time response against an influenza pandemic which is likely to hit developing countries hardest.

This agreement has seen preclinical and clinical study use of BioDiem's cold-adapted master donor LAIV virus bearing avian or human influenza virus genes from viruses with pandemic potential. PATH has provided financial and technical support to the Institute of Experimental Medicine and third party contractors to complete this important public health work.

PATH has also sponsored recent large clinical trials of LAIV in young children to assess safety and efficacy. The results of these are expected to be available in 2015.

Centers for Disease Control and Prevention (CDC)

The aim of the Cooperative Research and Development Agreement (CRADA) between BioDiem and the US Center for Disease Control and Prevention (CDC) was to develop a vaccine candidate against the H5N1 avian influenza based on BioDiem's technology. Preclinical studies to assess the infectivity, immunogenicity and protective efficacy of the H5N1 LAIV versus the standard inactivated influenza vaccine have been successfully completed. The results support the value of the LAIV vaccine technology in protection against the H5N1 virus. In particular it was demonstrated that the cell-based manufacturing method, which allows rapid scale up in the case of a pandemic, produced successful results and that the LAIV vaccine provided greater cross-protection against variants of the H5N1 virus than the inactivated vaccine. This feature could be extremely advantageous in the event of an avian flu outbreak. Also in such a situation, access to chicken eggs could be compromised and so the ability to manufacture flu vaccine rapidly in mammalian cells would give an advantage. Previous published work has demonstrated the efficacy of cell-produced LAIV vaccine vs. egg-produced vaccine in ferret studies.

VIVALIS (now Valneva)

In May 2012 BioDiem announced a research collaboration with France-based VIVALIS (now Valneva), a biopharmaceutical company with expertise in vaccine production technologies. The collaboration involved investigation into whether VALNEVA's technology could support the further development of the LAIV vector program. The successful results were reported in August 2012. VALNEVA provides innovative cell-based solutions to the pharmaceutical industry for the manufacture of vaccines and proteins, and develops drugs for the prevention and treatment of unmet medical needs.

Commercial Partners

More information about BioDiem's commercial flu vaccine partners, the Serum Institute of India (India), and Changchun BCHT Biotechnology Co. (China) can be found on our LAIV webpage.

Australian Research Institutions

BioDiem has strong ties to the world-class research institutions of Australia, which have assisted in the research and development of BioDiem's portfolio. These partners include:

  • The Australian National University
  • Monash University
  • RMIT University
  • Queensland Institute of Medical Research
  • University of Canberra
  • Centre for Infectious Diseases and Microbiology, Westmead
  • Griffith University
  • University of Western Sydney

About Our Disease Targets

We use our in-house expertise in development of therapeutics and in infectious disease plus our extensive partnership network to identify the best cost-effective commercial opportunities for portfolio value growth.

The focus on infectious diseases is timely. The worldwide anti-infectives market was worth more than US$53 billion in 2011 and has been projected to reach an astounding US$103 billion by 2015. Anti-infectives include the sales of antivirals, antifungals and antibacterials worldwide.

BioDiem's Development Work Currently Focuses on the Following Key Disease Targets:

Influenza: influenza is caused by a virus and is highly contagious. Illness can result in hospitalisation and death especially in the high-risk groups (children, elderly or chronically ill). Worldwide the annual epidemics are estimated to result in 3-5 million cases of severe illness, and about 250,000 to 500,000 deaths. Circulating flu virus strains can change and so vaccinations maybe required each year.

Tuberculosis: TB is an infection caused by a bacteria. Resistance to TB drugs is a global concern. TB commonly affects the lungs but can also affect other parts of the body. It is spread by droplets from the throat and lungs of infected people. It is second only to HIV/AIDS as the greatest killer worldwide due to a single infectious agent. In 2013, 9 million fell ill with TB, and 1.5 million died from TB. It is a leading killer of HIV-positive patients with an estimated one quarter of all HIV-related deaths caused by TB.

Sexually transmitted infection (STI): Trichomonas vaginalis, is the microorganism commonly responsible for the STI trichomoniasis. Trichomoniasis is an extremely common infection which usually causes inflammation and irritation of the urogenitary tract. Infection with trichomoniasis has been associated with increased likelihood of the development of some cancers, HIV infection and reproductive issues.

Serious bacterial infections, including Methicillin-resistant Staphylococcus aureus (MRSA): a strain of antibiotic-resistant bacteria of huge concern to global healthcare systems. The treatment options for this Golden Staph are increasingly limited as the resistant form spreads.

Invasive fungal infections, including Aspergillosis: fungal infections are growing problem in critically ill patients and an important cause of illness and death in patients being treated for cancers or in other diseases where the immune system is severely weakened by the disease or its treatments. Previously rare disease-causing fungi have emerged. Fungal infections can be resistant to current treatments. For example Aspergillosis can be difficult to cure and can prove fatal. Invasive aspergillosis is associated with a mortality rate of 30-95%.


Products

Technology and Products

BioDiem is an Australian-based biotechnology company with a focus on developing and commercialising vaccine and infectious disease therapies.

The strength of our global partnering network is a key advantage of the Company. Our partners (the World Health Organisation and the US National Institutes of Health among others) are world-leading institutions that have in some cases facilitated our access to major markets (e.g. China and India).

Our strategy is to grow a diverse infectious disease treatment and prevention portfolio.

We currently earn revenue through licensing of LAIV influenza vaccine technology to Indian and Chinese partners.

We are also leveraging our existing LAIV technology to develop as a viral vector. BioDiem has signed an agreement with RMIT University to investigate the use of LAIV to create new non-influenza vaccines.

In parallel to our LAIV technology commercialisation, we are developing BDM-I, a novel antimicrobial compound which has shown impressive and broad activity in screening studies against a range of pathogenic micro-organisms including bacteria, fungi and protozoa. The continued rise in antibiotic-resistant strains of bacteria such as the deadly MRSA, and the increasing problem of clinical fungal infections, have led to significant interest in compounds which may address the lack of treatment options. Patents for BDM-I have been granted worldwide.

BDM-E (epitalon) is a tetrapeptide in development for treatment of retinal (back-of-eye) disease. It has Orphan Drug designation from the United States Food and Drug Administration (FDA) for the treatment of Retinitis Pigmentosa. BDM-E is currently the subject of discussions with potential commercial partners.

LAIV

A Core Technology Advantage: Live Attenuated Influenza Virus (LAIV) Vaccine

BioDiem's lead asset is the Live Attenuated Influenza Virus (LAIV) vaccine technology. Our LAIV vaccine Licensing business involves out-licensing of the company's platform technology for the production of intranasal vaccines for the prevention of seasonal and pandemic influenza.

BioDiem has exclusive rights to commercialise the LAIV technology outside Russia and the Commonwealth of Independent States.

We currently have two commercial partners, in China and India, and our LAIV vaccine technology is also licensed to the World Health Organization (WHO) as part of the Global Pandemic Influenza Action Plan to Increase Vaccine Supply.

Our LAIV technology was developed at the prestigious Institute for Experimental Medicine (IEM), St Petersburg, Russia. In Russia the LAIV intranasal influenza vaccine has been approved and used for over fifty years in millions of people – children, adults and the elderly. BioDiem in-licensed the technology, and maintains a close and strong relationship with the IEM.

How Does the LAIV Influenza Vaccine Work?

laiv picThe LAIV vaccine is administered by nasal spray and induces a rapid immune response in the lining of the nose and pharynx. The vaccines are based on Master Donor Strains that have been rendered 'cold adapted' and temperature sensitive, so that they will not replicate readily at temperatures above 33°C (as found in the lungs). The administration of the vaccine stimulates a broad mucosal, cellular and humoral immune response (all of which are required to optimise the effective prevention of influenza), without causing the disease.

Unlike the more traditional influenza vaccines which are injected, the LAIV vaccine is given as a nasal spray.

Each year the strains of influenza circulating in the population change. The diagram shows how the LAIV vaccine is adjusted so that it is effective against the relevant strains (wild type), as recommended by the World Health Organization each year.

Why LAIV?

The Live Attenuated Influenza Virus vaccine has a number of advantages. Extensive clinical trials and over fifty years of use in Russia have established the safety and efficacy profile. The LAIV vaccine is suitable for rapid production via cell-based manufacture giving a high yield and can also be manufactured using eggs with an increased yield compared to other influenza vaccine technologies. First-in-human and proof- of-concept clinical trials have been completed in Europe for an LAIV vaccine manufactured using a mammalian cell-based method.

One major advantage of the LAIV vaccine over the standard influenza shot is that it is a nasal spray so does not require injections or trained personnel. This makes it easier to use and administer. It also appears that vaccination using the LAIV offers immunological advantages in that it produces immunity similar to natural infection thus creating a broader immune response involving mucosal, humoral and cellular immunity.

Clinical Study Results

It has been shown in many studies that the LAIV vaccine provides better herd immunity than inactivated vaccines. Herd immunity is where non-vaccinated people are protected because of the larger 'herd' of vaccinated people. In the Novgorod school study, it was observed that influenza morbidity was significantly lower among non-vaccinated pupils and staff, where more than 50% pupils were vaccinated, compared with those schools where pupils received inactivated influenza vaccine. [Rudenko LG, et al., (1993) Efficacy of live attenuated and inactivated influenza vaccines in schoolchildren and their unvaccinated contacts in Novgorod, Russia. J Infect Dis. 168:881–887].

It has been demonstrated that the LAIV vaccine provides protection against 'drifted' variants of influenza i.e. where the circulating wild type strain is different to that used in the influenza shots. In Russian clinical trials the LAIV vaccine provided 59% protection in situations in which the epidemic influenza strain was different from the vaccine strain virus. In years where the vaccine strain has not exactly matched the circulating strain of influenza, the standard inactivated flu shot has provided protection at little more than placebo rates. This is important because the yearly decisions by the WHO, on which influenza virus strain should be selected for production of seasonal vaccines, is based on an expectation of what strains will circulate. This can be extremely difficult to predict into the future. A broader protective vaccine has obvious advantages including in the case of avian influenza.

Collaborations with the Institute of Experimental Medicine, St Petersburg, the World Health Organization, the Centres of Disease Control and Prevention (CDC) and other international groups such as the Program for Appropriate Technology in Health (PATH) for the development of seasonal and pandemic influenza LAIV vaccines are in place. This includes vaccines in development for avian or bird flu.

World Health Organization (WHO) Program

BioDiem contributes to the WHO's Global Pandemic Influenza Action Plan by licensing the WHO to transfer an egg-based live attenuated influenza virus (LAIV) vaccine production technology to developing country manufacturers.

The agreement is a non-exclusive licence designed to support wider distribution of the LAIV influenza vaccine in developing countries. Whereas public sector usage is royalty-free, royalties will flow to BioDiem directly from private sector sales. BioDiem has private sector licences in place with Serum Institute of India and also Changchun BCHT Biotechnology Co, China.

BioDiem has authorised the Institute of Experimental Medicine (IEM) and the Centers for Disease Control and Prevention (CDC) to supply LAIV reassortants to the WHO for use by its sublicencees. The vaccines developed through the WHO program are manufactured using eggs.

BioDiem's licensing partners in India and China

The WHO has issued sublicences to the LAIV technology to the Serum Institute of India Ltd and the Government Pharmaceutical Organization, Thailand, and China-based Changchun BCHT Biotechnology Co. BioDiem has commercial licences with Serum Institute of India Ltd and Changchun BCHT Biotechnology Co.

In 2014 the Serum Institute of India launched its seasonal influenza (trivalent) intranasal vaccine, Nasovac-S™, in the Indian market. This followed on from SII's H1N1 (swine flu) pandemic vaccine, called Nasovac™, which had been launched in July 2010. These vaccines are a result of the WHO collaboration using BioDiem's technology. BioDiem receives royalty payments on sales of these vaccines in the private market.

In 2012 BioDiem licensed its LAIV vaccine technology to Changchun BCHT Biotechnology Co. (BCHT). This licence enables BioDiem to receive royalties from Chinese private sector market sales of seasonal and pandemic vaccines. Securing this second commercial licence for the LAIV technology was a significant milestone for BioDiem.

Facilitated by funding primarily from the WHO and PATH organisations, work is now completed on a new laboratory fit-out at the Institute of Experimental Medicine in Saint Petersburg to allow the Institute to handle highly pathogenic influenza strains e.g. bird flu. Any material generated will be made available for use in developing countries under the WHO's Global Pandemic Influenza Action Plan to Increase Vaccine Supply.

The arrangement with the WHO gives BioDiem the opportunity to realise income from royalties on sales in the private market in developing countries.

BioDiem's LAIV Technology in the Fight to Prepare for Influenza Pandemics

Outbreaks of influenza remain a serious concern to the global community as evidenced by the recent examples of H7N9 in China and occasional cases of H5N1 in other countries. Human-to-human transmission of highly pathogenic viruses is the concern, because of the potentially high mortality rate , and it is known that little change is needed in the genetic make-up of existing viruses for this possibility to eventuate. Therefore the advance preparation and testing of vaccine candidates which could be effective in such a situation is an important public health initiative.

Under an agreement with the World Health Organisation (WHO), the Institute of Experimental Medicine, St Petersburg, Russia prepares LAIV reassortant vaccine strains suitable for production of seasonal and also pandemic influenza vaccines. A range of pandemic LAIV strains based on BioDiem's LAIV technology has now been prepared and tested so that they could be available quickly in the event of an influenza pandemic (see Table 2).

LAIV Vaccine Candidates Have Already Been Produced in Order to be Prepared for Various Pandemic Scenarios.

The candidates include subtypes of H5N1, H5N2, H7N3, H1N1 and H2N2. Preparatory studies in ferrets (the animal model of choice for influenza) showed the candidates were safe, immunogenic and protected animals from challenge with homologous (same) and heterologous (similar) 'flu viruses. Also clinical trials (Phase I) showed safety and immunogenicity in healthy adult volunteers. The advantages of LAIV vaccines includes stimulation of both humoral (local and serum antibody) and cellular immune responses, whereas standard inactivated flu vaccines predominantly induce serum antibodies. In the case of a pandemic, the cross-reactive immune response induced by LAIV's would be beneficial to protect against a new pandemic, even if the pandemic strain is slightly different. In the case of a serious pandemic, such breadth of protection could be vitally important.

Cooperative Research and Development Agreement (CRADA)

The Cooperative Research and Development Agreement (CRADA) between BioDiem and the US Center for Disease Control and Prevention (CDC) was aimed to develop a vaccine candidate against the H5N1 avian influenza based on BioDiem's technology. Preclinical studies to assess the infectivity, immunogenicity and protective efficacy of the H5N1 LAIV versus the standard inactivated influenza vaccine were successfully completed. The results support the value of the LAIV vaccine technology in protection against the H5N1 virus.

It was found that the cell-based manufacturing method, which allows rapid scale up in the case of a pandemic, produced successful results. The LAIV vaccine provided greater cross-protection against variants of the H5N1 virus than an inactivated vaccine. Previous published work has demonstrated the efficacy of cell-produced LAIV vaccine vs. egg-produced vaccine in ferret studies.

BDM-I

BDM-I: Addressing Market Need for Next-Generation Antimicrobials

Infectious diseases often dominate the media headlines, including rising antibiotic resistance and fear of "super bugs". One serious problem facing the global community is that anti-infective treatments that were once effective now cannot be relied upon. There are some strains of infections including tuberculosis, malaria, pneumonia and gonorrhea that resist all known drugs.

Coincidentally, infections that used to be rare, are now more common for example community acquired multi-drug resistant strains (MRSA golden staph) or where patients with reduced immunity are living longer for example following cancer treatment, therapy for HIV or cystic fibrosis. Compounding the problem are the very few new technologies in development for treatment of infections. Rising concern surrounds ever-increasing resistance to our existing antibiotic treatments, and the consequent rise in morbidity and mortality associated with previously treatable conditions. The scene is therefore set for the discovery and development of new anti-infective treatments.

BioDiem's Antimicrobial in Development: BDM-I

BDM-I is a small molecule which has shown selective activity in the laboratory against a range of serious disease-causing germs. It has demonstrated broad-spectrum activity against a wide range of disease-causing microbes such as bacteria, fungi, and parasites. It is currently being researched as a treatment against 'superbugs' or antibiotic-resistant bacteria and fungi. These organisms are of major concern to international healthcare agencies as the number of available treatments for these infections shrinks. If successful in development, BDM-I could be used to treat a range of infections and be used in many different ways e.g. injection, eyedrop, cream, tablet, etc.

BDM-I has been tested in vitro against a range of disease-causing microbes such as the bacteria causing Golden Staph [methicillin-resistant Staph aureus (MRSA)] and tuberculosis [Mycobacterium tuberculosis], the disease-causing fungi Aspergillus fumigatus, Candida albicans, Scedosporium spp., Pneumocystis carinii and Candida glabrata, potential agents which could be used in biological warfare agents and other serious human pathogens including Plasmodium falciparum which causes malaria. While a range of microbes appears sensitive to BDM-I, its action appears selective i.e. not all strains of a genus have been shown to be sensitive. Some of the most sensitive organisms on minimum inhibitory concentration (MIC) screening have been fungal, including Pneumocystis and Scedosporium species.

Screening studies to investigate the scope of in vitro activity of BDM-I have been conducted by groups such as the U.S. National Institute of Allergy and Infectious Diseases (NIAID)[1,2], United States Army Medical Research Institute of Infectious Diseases (USAMRIID), University of Sydney, RMIT University and Queensland Institute of Medical Research (QIMR). Based on promising in vitro data, BDM-I is poised to progress to in vivo studies in various infectious disease preclinical models.

Investment is sought to take BDM-I to this next milestone of testing in preclinical models of infection to demonstrate proof-of-concept.

BDM-E

BDM-E: Epitalon Tetrapeptide

BioDiem is seeking licencees for BDM-E (epitalon). The technology is covered by the patent "Tetrapeptide revealing geroprotective effect, pharmacological substance on its basis and the method of its application". For further information or for licences, please contact info@biodiem.com.

BDM-E (epitalon) was discovered in Russia, and has been successfully used in some Russian clinics for the compassionate treatment of eye disorders including Retinitis Pigmentosa (RP). RP is a serious eye disease that causes progressive degeneration of the delicate light receptor cells in the retina, which over time diminishes night and peripheral vision and eventually leads to blindness. This condition affects between an estimated one in 3,000 to one in 5,000 people, equivalent to approximately 100,000 to 120,000 people in the U.S. alone, and 2–2.5 million people worldwide. There are no treatments currently that can prevent retinal degeneration or restore vision loss in this disease.

BioDiem has received Orphan Drug designation from the United States Food and Drug Administration (FDA) for BDM-E for the treatment of Retinitis Pigmentosa.

BioDiem's preclinical work in Retinitis Pigmentosa has demonstrated promise. In vivo studies have shown that BDM-E is able to reduce the degree of damage to the retinal cell layers. It has also been shown to exert a degree of protection over the retina in models of this disease. In another research model of light damage it prevented photoreceptor apoptosis (programmed cell death). Through the use of BDM-E in Russia and results of an earlier clinical trial, BDM-E has already shown a good safety profile in the dose administered.

Preclinical studies at Monash University and the University of Melbourne have demonstrated that BDM-E produces positive effects in retinopathy of prematurity, a model of eye disease. The research results were presented in July 2012 at the International Society of Eye Research (ISER) meeting in Berlin, Germany.

New Vaccines and Vectors

BioDiem has an existing revenue-generating business from the licensing of its Live Attenuated Influenza Virus (LAIV) vaccine technology to partners in India and China. However, BioDiem is also focused on the development of new vaccines and therapies. BioDiem's in-house technologies, and its expertise surrounding the LAIV means the potential exists to design new vaccines, and use the LAIV as a 'shell' or 'vector' to jump-start the immune system and treat or prevent disease.

SAVINE (Scrambled Antigen Vaccine) Technology

SAVINE is a technology to design and customise immune-stimulation proteins (antigens) for use in new vaccine design. To request further information on the SAVINE technology, please contact info@biodiem.com.

LAIV Vector

Viruses have the ability to generate proteins prolifically. Viral vectors are viruses which are used to deliver antigens i.e. specific disease-proteins to generate a desirable immune response in the person who has been vaccinated. A wide range of diseases can be targeted depending on the choice of antigen which is presented by the viral vector. Various viruses have been tried for this purpose i.e. to produce specific proteins of diseases which are unrelated to the carrier virus. Unfortunately these viruses often have disadvantages. For example, they are weak and therefore by being weak, are safe, but often may be too weak to generate the strong immune response which is needed for protection or treatment.

The LAIV vector research aims to produce a platform technology to assist in the design of vaccines for different diseases including cancers. The advantage of the LAIV virus technology is that it has a documented safety profile from its use in Russia over many years and through its use in the European clinical trial program as an influenza vaccine.

LAIV-Vector-1024x673BioDiem is seeking interest from parties with expertise to collaborate in the next stages of the program leading to proof-of-concept.


Price History

52 Week High Change from 52 Week High % Change from 52 Week High 52 Week Low Change from 52 Week Low % Change from 52 Week Low
${{quote["Year's High"]}} ${{(quote["Historic Close"] - quote["Year's High"]) | setDecimalCheckForNa}} {{(((quote["Historic Close"] / quote["Year's High"]) - 1) * 100) | setDecimalCheckForNa}}% ${{quote["Year's Low"] | setDecimalCheckForNa}} ${{(quote["Historic Close"] - quote["Year's Low"])| setDecimalCheckForNa}} {{(((quote["Historic Close"] / quote["Year's Low"]) - 1) * 100) | setDecimalCheckForNa}}%
Date Open High Low Close Volume

Dividend Information

Dividend Yield Dividend Yield (5 Yr Avg) ISIN Stock Code (RIC) SEDOL Dividend Currency
{{ratios.Valuation.DivYield_CurTTM.Value | setDecimalCheckForNa}} {{ratios.Valuation.YLD5YAVG.Value | setDecimalCheckForNa}} {{Dividends[0].ISIN}} {{Dividends[0].RIC}} {{Dividends[0].SEDOL}} {{Dividends[0].DividendCurrency != '' ? Dividends[0].DividendCurrency : '-'}}

Year CorpActID DPTD DivAnnDate DivExDate DivPayDate DTMD DivRate DRD DRPrice DTMD DTMD Frank%
{{item.DividendExDate == '00/01/1900' ? '-' : item.DividendExDate}} {{item.CorporateActionsID}} {{item.DividendPaymentTypeDescription}} {{item.DividendAnnoucementDate == '00/01/1900' ? '-' : item.DividendAnnoucementDate}} {{item.DividendExDate == '00/01/1900' ? '-' : item.DividendExDate}} {{item.DividendPayDate == '00/01/1900' ? '-' : item.DividendPayDate}} {{item.DividendTypeMarkerDescription}} {{item.DividendRate != '0' ? item.DividendRate : '-'}} {{item.DividendReinvestmentDeadline == '00/01/1900' ? '-' : item.DividendReinvestmentDeadline}} {{item.DividendReinvestmentPrice != '0' ? item.DividendReinvestmentPrice : '-'}} {{item.DividendTaxMarkerDescription != '' ? item.DividendTaxMarkerDescription : '-'}} {{item.DividendTaxRate != '0' ? item.DividendTaxRate :'-'}} {{item.FrankingPercent != '0' ? item.FrankingPercent : '-'}}

Share Statistics

  Revenue/Share Free Cash Flow Per Share Cash Flow Per Share Book Value Per Share Book Value(tangible) Per Share Cash Per Share
Most Recent Quarter - - - {{ratios['Per share data'].QBVPS.Value | setDecimalCheckForNa}} {{ratios['Per share data'].QTANBVPS.Value | setDecimalCheckForNa}} {{ratios['Per share data'].QCSHPS.Value | setDecimalCheckForNa}}
Most Recent Fiscal Year {{ratios['Per share data'].AREVPS.Value | setDecimalCheckForNa}} - {{ratios['Per share data'].ACFSHR.Value | setDecimalCheckForNa}} {{ratios['Per share data'].ABVPS.Value | setDecimalCheckForNa}} {{ratios['Per share data'].ATANBVPS.Value | setDecimalCheckForNa}} {{ratios['Per share data'].ACSHPS.Value | setDecimalCheckForNa}}
Trailing 12 Months {{ratios['Per share data'].TTMREVPS.Value | setDecimalCheckForNa}} {{ratios['Per share data'].TTMFCFSHR.Value | setDecimalCheckForNa}} {{ratios['Per share data'].TTMCFSHR.Value | setDecimalCheckForNa}} - - -
  Dividend Per Share EPS Normalized EPS Basic Exluding Extraordinary Items EPS Including Extraordinary Items EPS Excluding Extraordinary Items EBITD Per Share
Most Recent Fiscal Year {{ratios['Per share data'].ADIVSHR.Value | setDecimalCheckForNa}} {{ratios['Per share data'].AEPSNORM.Value | setDecimalCheckForNa}} {{ratios['Per share data'].ABEPSXCLXO.Value | setDecimalCheckForNa}} {{ratios['Per share data'].AEPSINCLXO.Value | setDecimalCheckForNa}} {{ratios['Per share data'].AEPSXCLXOR.Value | setDecimalCheckForNa}} -
Trailing 12 Months {{ratios['Per share data'].TTMDIVSHR.Value | setDecimalCheckForNa}} - {{ratios['Per share data'].TTMBEPSXCL.Value | setDecimalCheckForNa}} {{ratios['Per share data'].TTMEPSINCX.Value | setDecimalCheckForNa}} {{ratios['Per share data'].TTMEPSXCLX.Value | setDecimalCheckForNa}} {{ratios['Per share data'].TTMEBITDPS.Value | setDecimalCheckForNa}}
5 Year Average {{ratios['Per share data'].ADIV5YAVG.Value | setDecimalCheckForNa}} - - - - -
Avg Vol(3 month) Avg Vol(10 day) Shares Outstanding Float % Held by Insiders % Held by Institutions Shares Short Shares Ratio Short % of Float Shares Short(prior month)
{{ratios['Price and Volume'].VOL3MAVG.Value | checkForNa}} {{ratios['Price and Volume'].VOL10DAVG.Value | checkForNa}} - - - - - - - -
Common Shareholders Shares Outstanding Shares Issued Float
{{generalInfo.CompanyGeneralInfo.CommonShareholders.Value | checkForNa}} {{sharesIssuedData.SharesOut | abbreviateNumber | checkForNa}} {{sharesIssuedData.SharesIssued | abbreviateNumber | checkForNa}} {{sharesIssuedData.Float | abbreviateNumber | checkForNa}}
Index Code Index name
{{item}} {{generalInfo.IndexMembership[item]}}
N/A N/A
Order Industry Type Code Mnemonic Reported
N/AN/AN/AN/AN/AN/A
{{detail.Order | checkForNa}} {{detail.Description | checkForNa}} {{industry | checkForNa}} {{detail.Code | checkForNa}} {{detail.Mnemonic | checkForNa}}

Valuation Ratios

  P/E excluding extraordinary items P/E Normalized P/E Basic excluding extraordinary items P/E excluding extraordinary items high P/E excluding extraordinary items low P/E including extraordinary items
Most Recent Fiscal Year {{ratios.Valuation.APEEXCLXOR.Value | setDecimalCheckForNa}} {{ratios.Valuation.APENORM.Value | setDecimalCheckForNa}} - - - -
TTM {{ratios.Valuation.PEEXCLXOR.Value | setDecimalCheckForNa}} - {{ratios.Valuation.PEBEXCLXOR.Value | setDecimalCheckForNa}} {{ratios.Valuation.TTMPEHIGH.Value | setDecimalCheckForNa}} {{ratios.Valuation.TTMPELOW.Value | setDecimalCheckForNa}} {{ratios.Valuation.PEINCLXOR.Value | setDecimalCheckForNa}}
  Price to Sales Price to Tangible Book Price to Free Cash Flow per Share Price to Cash Flow per Share Price to Book
Most Recent Fiscal Year {{ratios.Valuation.APR2REV.Value | setDecimalCheckForNa}} {{ratios.Valuation.APR2TANBK.Value | setDecimalCheckForNa}} {{ratios.Valuation.APRFCFPS.Value | setDecimalCheckForNa}} - {{ratios.Valuation.APRICE2BK.Value | setDecimalCheckForNa}}
Trailing 12 Months {{ratios.Valuation.TTMPR2REV.Value | setDecimalCheckForNa}} - {{ratios.Valuation.TTMPRFCFPS.Value | setDecimalCheckForNa}} {{ratios.Valuation.TTMPRCFPS.Value | setDecimalCheckForNa}} -
Most Recent Quarter - {{ratios.Valuation.PR2TANBK.Value | setDecimalCheckForNa}} - - {{ratios.Valuation.PRICE2BK.Value | setDecimalCheckForNa}}
Dividend Yield - 5 Year Average {{ratios.Valuation.YLD5YAVG.Value | setDecimalCheckForNa}}
Dividend Yield - indicated annual dividend divided by closing price {{ratios.Valuation.YIELD.Value | setDecimalCheckForNa}}
Current Dividend Yield - Common Stock Primary Issue, LTM {{ratios.Valuation.DivYield_CurTTM.Value | setDecimalCheckForNa}}
Net Debt, LFI {{ratios.Valuation.NetDebt_I.Value | setDecimalCheckForNa}}
Net Debt, LFY {{ratios.Valuation.NetDebt_A.Value | setDecimalCheckForNa}}

Financial Strength Ratios

  Current ratio Quick ratio LT debt/equity Total debt/total equity
Most Recent Quarter {{ratios['Financial strength'].QCURRATIO.Value | setDecimalCheckForNa}} {{ratios['Financial strength'].QQUICKRATI.Value | setDecimalCheckForNa}} {{ratios['Financial strength'].QLTD2EQ.Value | setDecimalCheckForNa}} {{ratios['Financial strength'].QTOTD2EQ.Value | setDecimalCheckForNa}}
Most Recent Fiscal Year {{ratios['Financial strength'].ACURRATIO.Value | setDecimalCheckForNa}} {{ratios['Financial strength'].AQUICKRATI.Value | setDecimalCheckForNa}} {{ratios['Financial strength'].ALTD2EQ.Value | setDecimalCheckForNa}} {{ratios['Financial strength'].ATOTD2EQ.Value | setDecimalCheckForNa}}
  Payout ratio Current EV/Free Cash Flow Interest coverage Total debt/total equity
Most Recent Fiscal Year {{ratios['Financial strength'].APAYRATIO.Value | setDecimalCheckForNa}} {{ratios['Financial strength'].EV2FCF_CurA.Value | setDecimalCheckForNa}} {{ratios['Financial strength'].AINTCOV.Value | setDecimalCheckForNa}} {{ratios['Financial strength'].ATOTD2EQ.Value | setDecimalCheckForNa}}
Trailing 12 Months {{ratios['Financial strength'].TTMPAYRAT.Value | setDecimalCheckForNa}} {{ratios['Financial strength'].EV2FCF_CurTTM.Value | setDecimalCheckForNa}} {{ratios['Financial strength'].TTMINTCOV.Value | setDecimalCheckForNa}} -
Income Statement Revenue EBITD Earnings before taxes Net Income available to common Earnings before taxes Normalized Earnings per Share, Normalized, Excluding Extraordinary Items, Avg. Diluted Shares Outstanding
Most Recent Fiscal Year {{ratios['Income Statement'].AREV.Value | setDecimalCheckForNa}} {{ratios['Income Statement'].AEBITD.Value | setDecimalCheckForNa}} {{ratios['Income Statement'].AEBT.Value | setDecimalCheckForNa}} {{ratios['Income Statement'].ANIAC.Value | setDecimalCheckForNa}} {{ratios['Income Statement'].AEBTNORM.Value | setDecimalCheckForNa}} -
Trailing 12 Months {{ratios['Income Statement'].TTMREV.Value | setDecimalCheckForNa}} {{ratios['Income Statement'].TTMEBITD.Value | setDecimalCheckForNa}} {{ratios['Income Statement'].TTMEBT.Value | setDecimalCheckForNa}} {{ratios['Income Statement'].TTMNIAC.Value | setDecimalCheckForNa}} - {{ratios['Income Statement'].VDES_TTM.Value | setDecimalCheckForNa}}
  Gross Margin Net Profit Margin % Operating Margin Pre Tax Margin Free Operating Cash Flow/Revenue
1st Historical Fiscal Year {{ratios.Margins.AGROSMGN.Value | setDecimalCheckForNa}} {{ratios.Margins.ANPMGNPCT.Value | setDecimalCheckForNa}} {{ratios.Margins.AOPMGNPCT.Value | setDecimalCheckForNa}} {{ratios.Margins.APTMGNPCT.Value | setDecimalCheckForNa}} -
Trailing 12 Months {{ratios.Margins.TTMGROSMGN.Value | setDecimalCheckForNa}} {{ratios.Margins.TTMNPMGN.Value | setDecimalCheckForNa}} {{ratios.Margins.TTMOPMGN.Value | setDecimalCheckForNa}} {{ratios.Margins.TTMPTMGN.Value | setDecimalCheckForNa}} {{ratios.Margins.Focf2Rev_TTM.Value | setDecimalCheckForNa}}
5 Year Average {{ratios.Margins.GROSMGN5YR.Value | setDecimalCheckForNa}} {{ratios.Margins.MARGIN5YR.Value | setDecimalCheckForNa}} {{ratios.Margins.OPMGN5YR.Value | setDecimalCheckForNa}} {{ratios.Margins.PTMGN5YR.Value | setDecimalCheckForNa}} {{ratios.Margins.Focf2Rev_AAvg5.Value | setDecimalCheckForNa}}
Risk Ratio Current Ratio Quick Ratio Interest Coverage LT Debt/Equity Total Debt/Total equity
Most Recent Quarter {{ratios['Financial strength'].QCURRATIO.Value | setDecimalCheckForNa}} {{ratios['Financial strength'].QQUICKRATI.Value | setDecimalCheckForNa}} - {{ratios['Financial strength'].QLTD2EQ.Value | setDecimalCheckForNa}} {{ratios['Financial strength'].QTOTD2EQ.Value | setDecimalCheckForNa}}
Most Recent Fiscal Year {{ratios['Financial strength'].ACURRATIO.Value | setDecimalCheckForNa}} {{ratios['Financial strength'].AQUICKRATI.Value | setDecimalCheckForNa}} {{ratios['Financial strength'].AINTCOV.Value | setDecimalCheckForNa}} {{ratios['Financial strength'].ALTD2EQ.Value | setDecimalCheckForNa}} {{ratios['Financial strength'].ATOTD2EQ.Value | setDecimalCheckForNa}}
Trailing 12 Months - - {{ratios['Financial strength'].TTMINTCOV.Value | setDecimalCheckForNa}} - -

Management Effectiveness Ratios

Turnover Asset Inventory Receivables
Most Recent Fiscal Year {{ratios['Mgmt Effectiveness'].AASTTURN.Value | setDecimalCheckForNa}} {{ratios['Mgmt Effectiveness'].AINVTURN.Value | setDecimalCheckForNa}} {{ratios['Mgmt Effectiveness'].ARECTURN.Value | setDecimalCheckForNa}}
Trailing 12 Months {{ratios['Mgmt Effectiveness'].TTMASTTURN.Value | setDecimalCheckForNa}} {{ratios['Mgmt Effectiveness'].TTMINVTURN.Value | setDecimalCheckForNa}} {{ratios['Mgmt Effectiveness'].TTMRECTURN.Value | setDecimalCheckForNa}}
Return on Average Assets EBITD Equity Investment
Most Recent Fiscal Year {{ratios['Mgmt Effectiveness'].AROAPCT.Value | setDecimalCheckForNa}} - {{ratios['Mgmt Effectiveness'].AROEPCT.Value | setDecimalCheckForNa}} {{ratios['Mgmt Effectiveness'].AROIPCT.Value | setDecimalCheckForNa}}
Trailing 12 Months {{ratios['Mgmt Effectiveness'].TTMROAPCT.Value | setDecimalCheckForNa}} - {{ratios['Mgmt Effectiveness'].TTMROEPCT.Value | setDecimalCheckForNa}} {{ratios['Mgmt Effectiveness'].TTMROIPCT.Value | setDecimalCheckForNa}}
5 Year Average {{ratios['Mgmt Effectiveness'].AROA5YAVG.Value | setDecimalCheckForNa}} - {{ratios['Mgmt Effectiveness'].AROE5YAVG.Value | setDecimalCheckForNa}} {{ratios['Mgmt Effectiveness'].AROI5YRAVG.Value | setDecimalCheckForNa}}
Employees Net Income Revenue
Most Recent Fiscal Year {{ratios['Mgmt Effectiveness'].ANIPEREMP.Value | setDecimalCheckForNa}} {{ratios['Mgmt Effectiveness'].AREVPEREMP.Value | setDecimalCheckForNa}}
Trailing 12 Months {{ratios['Mgmt Effectiveness'].TTMNIPEREM.Value | setDecimalCheckForNa}} {{ratios['Mgmt Effectiveness'].TTMREVPERE.Value | setDecimalCheckForNa}}

Growth Ratios

Growth Rates Revenue % EPS Dividend Revenue/Share Book Value Per Share Capital Spending Net Profit Margin
Most Recent Quarter 1 Year Ago {{ratios.Growth.REVCHNGYR.Value | setDecimalCheckForNa}} {{ratios.Growth.EPSCHNGYR.Value | setDecimalCheckForNa}} - - - - -
5 Years {{ratios.Growth.REVTRENDGR.Value | setDecimalCheckForNa}} {{ratios.Growth.EPSTRENDGR.Value | setDecimalCheckForNa}} - {{ratios.Growth.REVPS5YGR.Value | setDecimalCheckForNa}} {{ratios.Growth.BVTRENDGR.Value | setDecimalCheckForNa}} {{ratios.Growth.CSPTRENDGR.Value | setDecimalCheckForNa}} {{ratios.Growth.NPMTRENDGR.Value | setDecimalCheckForNa}}
3 Years {{ratios.Growth.REVGRPCT.Value | setDecimalCheckForNa}} {{ratios.Growth.EPSGRPCT.Value | setDecimalCheckForNa}} {{ratios.Growth.DIVGRPCT.Value | setDecimalCheckForNa}} - - - -
TTM over TTM {{ratios.Growth.EPSTRENDGR.Value | setDecimalCheckForNa}} {{ratios.Growth.TTMEPSCHG.Value | setDecimalCheckForNa}} - - - - -
CAGR Free Operating Cash Flow Earnings Before Interest, Taxes, Depreciation & Amortization Tangible Book Value Total Debt
5 Year CAGR {{ratios.Growth.FOCF_AYr5CAGR.Value | setDecimalCheckForNa}} {{ratios.Growth.Ebitda_AYr5CAGR.Value | setDecimalCheckForNa}} {{ratios.Growth.TanBV_AYr5CAGR.Value | setDecimalCheckForNa}} {{ratios.Growth.STLD_AYr5CAGR.Value | setDecimalCheckForNa}}
5 Year Interim CAGR - {{ratios.Growth.Ebitda_TTMY5CAGR.Value | setDecimalCheckForNa}} - -

Forecast Ratios

Projected Sales ProjSalesH ProjSalesL ProjSalesNumOfEst ProjSalesPS
{{forecasts.ProjSales | setDecimalCheckForNa}} {{forecasts.ProjSalesH | setDecimalCheckForNa}} {{forecasts.ProjSalesL | setDecimalCheckForNa}} {{forecasts.ProjSalesNumOfEst | setDecimalCheckForNa}} {{forecasts.ProjSalesPS | setDecimalCheckForNa}}
ProjSalesQ ProjSalesQH ProjSalesQL ProjSalesQNumOfEst Price2ProjSales
{{forecasts.ProjSalesQ | setDecimalCheckForNa}} {{forecasts.ProjSalesQH | setDecimalCheckForNa}} {{forecasts.ProjSalesQL | setDecimalCheckForNa}} {{forecasts.ProjSalesQNumOfEst | setDecimalCheckForNa}} {{forecasts.Price2ProjSales | setDecimalCheckForNa}}
ProjEPS ProjEPSHigh ProjEPSLow ProjEPSNumOfEst ProjEPSQ
{{forecasts.ProjEPS | setDecimalCheckForNa}} {{forecasts.ProjEPSH | setDecimalCheckForNa}} {{forecasts.ProjEPSL | setDecimalCheckForNa}} {{forecasts.ProjEPSNumOfEst | setDecimalCheckForNa}} {{forecasts.ProjEPSQ | setDecimalCheckForNa}}
ProjEPSQH ProjEPSQL ProjEPSQNumOfEst ProjPE ProjLTGrowthRate
{{forecasts.ProjEPSQH | setDecimalCheckForNa}} {{forecasts.ProjEPSQL | setDecimalCheckForNa}} {{forecasts.ProjEPSQNumOfEst | setDecimalCheckForNa}} {{forecasts.ProjPE | setDecimalCheckForNa}} {{forecasts.ProjLTGrowthRate | setDecimalCheckForNa}}
TargetPrice EPSActual EPSPrev EPSSurprise EPSSurprisePrc
{{forecasts.TargetPrice | setDecimalCheckForNa}} {{forecasts.EPSActual | setDecimalCheckForNa}} {{forecasts.EPSPrev | setDecimalCheckForNa}} {{forecasts.EPSSurprise | setDecimalCheckForNa}} {{forecasts.EPSSurprisePrc | setDecimalCheckForNa}}
EPSActualQ EPSPrevQ EPSSurpriseQ EPSSurpriseQPrc
{{forecasts.EPSActualQ | setDecimalCheckForNa}} {{forecasts.EPSPrevQ | setDecimalCheckForNa}} {{forecasts.EPSSurpriseQ | setDecimalCheckForNa}} {{forecasts.EPSSurpriseQPrc | setDecimalCheckForNa}}
ProjProfit ProjProfitH ProjProfitL ProjProfitNumOfEst
{{forecasts.ProjProfit | setDecimalCheckForNa}} {{forecasts.ProjProfitH | setDecimalCheckForNa}} {{forecasts.ProjProfitL | setDecimalCheckForNa}} {{forecasts.ProjProfitNumOfEst | setDecimalCheckForNa}}
ProjDPS ProjDPSH ProjDPSL ProjDPSNumOfEst
{{forecasts.ProjDPS | setDecimalCheckForNa}} {{forecasts.ProjDPSH | setDecimalCheckForNa}} {{forecasts.ProjDPSL | setDecimalCheckForNa}} {{forecasts.ProjDPSNumOfEst | setDecimalCheckForNa}}

Financial Reports

Financial Summary

Last Updated: {{generalInfo.TextInfo['Financial Summary'].LastUpdated}}

{{generalInfo.TextInfo['Financial Summary'].Value && generalInfo.TextInfo['Financial Summary'].Value != ''? generalInfo.TextInfo['Financial Summary'].Value: 'No Financial Summary Found.'}}


Accounting Notes
Fiscal Year Ends Most Recent Quarter Transfer agent Auditor Shariah Compliant

{{generalInfo.CompanyGeneralInfo.TotalSharesOut.Data | date:'dd/MM/yyyy' }}

-

- - {{generalInfo.Auditor && generalInfo.Auditor != ''? generalInfo.Auditor : '-'}}
Fiscal Period
Period End Date:
Period Length
Ratios Value
Analyst Footnotes

Last Updated: {{generalInfo.TextInfo['Analyst Footnotes'].LastUpdated}}

{{generalInfo.TextInfo['Analyst Footnotes'].Value && generalInfo.TextInfo['Analyst Footnotes'].Value != '' ? generalInfo.TextInfo['Analyst Footnotes'].Value : 'No Analyst Footnotes Found.'}}



Directors, Officers & Company Executives

Start Date End Date
{{personobject.PersonInformation.Name.Info| getDirectorFullNameIncludingPrefix}}
{{persontitlesobject.Value}}, {{persontitles.Start.Day}}-{{persontitles.Start.Month}}-{{persontitles.Start.Year}} {{persontitles.End.Day}}-{{persontitles.End.Month}}-{{persontitles.End.Year}}
No Directors, Officers & Company Executives Information Found.

Recommendation Statistics

No Recommendation Statistics

Recommendation Statistics
Recommendation Number Of Analysts
{{stats.Recommendation}} {{stats.NumberOfAnalysts}}
I/B/E/S Mean
{{verdict[meanmarker]}} {{analystvotes}} Analysts Mean recommendation from all analysts covering the company on a standardized 5-point scale.
  • Sell
  • Reduce
  • Hold
  • Buy
  • Strong Buy

Past Broker Recommendations

No Past Recommendations

Past Broker Recommendations
  Strong Buy Buy Hold Underperform Sell Total
{{snapshots.Age === 1 ? "1 Week Ago" : (snapshots.Age === 2 ? "30 Days Ago" : (snapshots.Age === 3 ? "60 Days Ago" : (snapshots.Age === 4 ? "90 Days Ago" : "")))}} {{snapshots.Statistics[0].NumberOfAnalysts}} {{snapshots.Statistics[1].NumberOfAnalysts}} {{snapshots.Statistics[2].NumberOfAnalysts}} {{snapshots.Statistics[3].NumberOfAnalysts}} {{snapshots.Statistics[4].NumberOfAnalysts}} {{snapshots.NumberOfRecommendations}}

Target Price

No Target Price

Target Price
Mean {{priceTarget.Mean}}
High {{priceTarget.High}}
Low {{priceTarget.Low}}
Median {{priceTarget.Median}}
Standard Devitation {{priceTarget.StandardDeviation}}
Number Of Estimates {{priceTarget.NumberOfEstimates}}

Videos

No Videos Found

Click here to view video

{{video.summary}}




Contact Info

BIODIEM LTD

Level 4
100 Albert Road
South Melbourne, VIC
Australia, 3205

Phone: +61 3 9692 7240
Fax: +61 3 9077 9233
Email: info@biodiem.com
Website: http://www.biodiem.com

Click here to view the interactive map
BIODIEM LTD Google Map
BIODIEM LTD Google Map

Home

Search

Login

Report a bug